Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals

PET Clin. 2024 Apr 23:S1556-8598(24)00018-X. doi: 10.1016/j.cpet.2024.03.003. Online ahead of print.ABSTRACTNovel prostate-specific membrane antigen (PSMA) ligands labeled with α-emitting radionuclides are sparking a growing interest in prostate cancer treatment. These targeted alpha therapies (TATs) have attractive physical properties that deem them effective in progressive metastatic castrate-resistant prostate cancer (mCRPC). Among the PSMA TAT radiopharmaceuticals, [225Ac]Ac-PSMA has been used extensively on a compassionate basis and is currently undergoing phase I trials. Notably, TAT has the potential to improve quality of life and has favorable antitumor activity and outcomes in multiple scenarios other than in mCRPC. In addition, resistance mechanisms to TAT may be amenable to combination therapies.PMID:38658230 | DOI:10.1016/j.cpet.2024.03.003
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research